AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition

Loading news article.

AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition | WAPE

Article summary